Navigation Links
Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
Date:9/22/2009

BERLIN, Sept. 22 /PRNewswire/ -- Bayer today announced results from a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase inhibitor, which demonstrated that treatment with regorafenib resulted in a 31 percent partial response rate and 50 percent stabilization rate in patients with metastatic renal cell carcinoma (RCC). These data were presented in an oral session at the joint 15th Congress of the European CanCer Organisation and 34th Congress of the European Society for Medical Oncology (ECCO 15 - 34th ESMO). Preliminary results from this study were presented earlier this year at the 45th American Society of Clinical Oncology (ASCO) Annual Congress, May 29 - June 2, 2009, Orlando, Florida.

"Bayer is committed to researching and developing potential anti-cancer agents like regorafenib, which may eventually help physicians and patients manage this devastating disease," said Kemal Malik, MD, Member of the Board of Management of Bayer Schering Pharma AG and Head of Global Development. "We look forward to continuing the comprehensive clinical development program for regorafenib, which we believe could potentially represent a promising new treatment option for various tumor types."

At the time of data analysis, 81 percent of patients (n=48) in the trial experienced disease stabilization or regression. Specifically, 31 percent of patients (n=15) experienced a confirmed partial response (PR), according to the Response Evaluation Criteria in Solid Tumors (RECIST), and 50 percent of patients (n=24) experienced stable disease (SD). The data also showed an estimated median progression-free survival of 8.3 months at the time of protocol-defined end of study. Importantly, the time of data analyses, which occurred on May 31, 2009, was prospectively defined in the protocol as when the last patient was treated for at least six months. At the time of analysi
'/>"/>

SOURCE Bayer HealthCare
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014  Medical Science Liaisons play ... key link between the medical device industry and key ... in the coming years as the device industry relies ... According to research by benchmarking firm, Best Practices, LLC, ... an important edge is by harnessing new technology to ...
(Date:12/22/2014)... 2014 NxStage Medical, Inc. (NASDAQ: ... products, announced today that the U.S. Food and ... to perform hemodialysis overnight while the patient is ... NxStage,s® System One is the first and only ... indication. Home nocturnal hemodialysis is ...
(Date:12/22/2014)... 22, 2014 Research and Markets ( ... "US Self-monitoring Blood Glucose Market" report to their ... This market insight focuses on the developments in ... United States . Reimbursement analysis and the effects ... for more than 73 SMBG meters have been performed, ...
Breaking Medicine Technology:Role of Medical Science Liaisons Evolving in Medical Device Sector 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3US Self-monitoring Blood Glucose Market 2
... Group Inc. (Nasdaq: WWIN ; "Winner Medical" or ... and non-woven fabric made from 100% natural PurCotton® products in ... the 2011 Brean Murray, Carret & Co. Beijing China Growth ... at the JW Marriott Hotel located at 83 Jian Guo ...
... SAN DIEGO, June 22, 2011 OncoSec Medical Incorporated ... ElectroOncology therapies to treat solid tumor cancers, announced today ... to OncoSec,s board of directors and will chair its ... For over 20 years, Dr. Maida has ...
Cached Medicine Technology:Winner Medical to Present at Brean Murray, Carret & Co. Beijing China Growth Conference 2Winner Medical to Present at Brean Murray, Carret & Co. Beijing China Growth Conference 3OncoSec Medical Announces the Appointment of Dr. Anthony E. Maida, III, to Its Board of Directors 2OncoSec Medical Announces the Appointment of Dr. Anthony E. Maida, III, to Its Board of Directors 3
(Date:12/26/2014)... 2014 “Many people become overwhelmed by ... claim issues and phone calls with insurance companies,” The ... featuring their free eBook on pedestrian and bicycle ... pedestrian and bicycle auto accident claims assures the injured ... of professionally handling their case while they focus on ...
(Date:12/26/2014)... (PRWEB) December 26, 2014 Parker ... for the best in heating, cooling and plumbing ... 24 hour emergency services in 2014 with regard ... know that Arizona is known for its incredibly ... that understands the intricacies and details of a ...
(Date:12/25/2014)... December 26, 2014 The report ... to 2023” focuses on the current treatment landscape, ... the colorectal cancer market. Stivarga is a drug ... or rectal cancer. Boehringer Ingelheim is developing nintedanib ... treatment of refractory CRC in the US, Europe, ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 Recently, iFitDress.com, the ... for women, has announced its new selection of black ... are on sale now; they are available at discounted prices, ... says, “The promotion will last for three weeks only. You ... market. Those who are interested in our new items can ...
(Date:12/25/2014)... BambooFlooringChina.com sells many bamboo products and the business is ... company announces big discounts on its bamboo mats , ... is the world’s leader in bamboo flooring. According to ... 20, 2015. , The bamboo mats are made from ... All the bamboo strips for the mats are boiled ...
Breaking Medicine News(10 mins):Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... Who should decide for the disabled? Can parents arrange surgical interventions ... them? Such questions are being a raised in a beated debate ... a debilitating disorder. Her brain stopped developing when she was only ... She seems at times to recognize her family members and to ...
... House Press Secretary Tony Snow has bad news. His colon ... resurfaced//. ,Snow was treated with chemotherapy in ... satellite growths of tumors that could be metastatic. Yet after ... area, doctors discovered additional tumors in his liver. ...
... design Hormone-based Heart pill to control high blood pressure ... ,Mayo Clinic researchers have designed two promising ... be given in pill form to lower high blood ... both heart and kidney function. ,In ...
... common injury among children, yet the number of pediatric ... of children is decreasing nationwide. The management of fractures ... knowledge and training is needed to provide the best ... New York’s Hospital for Special Surgery (HSS). ...
... claim that sequence variation in a gene linked to ... but also to a craving for alcohol.// ... role in the regulation of dopamine function. SNCA mutations ... disorder Parkinson's disease, which is caused by a substantially ...
... are receiving MMR shots, say official figures.// ... two-year-olds were given the jab, which protects against measles, mumps and ... , Yet, this is an increase from the previous ... ,MMR vaccines were introduced in 1988, but levels of uptake began ...
Cached Medicine News:Health News:Debate in US: Who Should Decide for Disabled People? 2Health News:White House Press Secretary to Battle Second Round of Colon Cancer 2Health News:Hormone-based Heart Pill to Control High Blood Pressure 2Health News:Hormone-based Heart Pill to Control High Blood Pressure 3Health News:Number of Specialists Best at Treating Children's Fractures Decreasing 2Health News:Number of Specialists Best at Treating Children's Fractures Decreasing 3Health News:Not Parkinson’s Disease Alon 2Health News:Scotland’s Parents Still a Little Wary of MMR Shot 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: